🇺🇸 FDA

Company profile · Sponsor

pharmaand

pharmaand GmbH

E5F8398 · EMA pharma Wien, AT
Pipeline
1
Drugs
0
Patents
0

Quick answer

pharmaand (E5F8398) is a pharma company. headquartered in Wien, AT. listed on EMA. NovaPharmaNews links 1 pipeline program, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E5F8398
Exchange EMA
Company type pharma
Headquarters Wien, AT

Pipeline (1)

Search pipeline →

  1. Placebo for Opdivo, Rubraca 200 mg film-coated tablets, Rubraca 250 mg film-coated tablets, Rubraca 300 mg film-coated tablets, OPDIVO 10 mg/mL concentrate for solution for infusion., Placebo for Rubraca

    pharmaand

    Ovarian epithelial cancer, Malignant peritoneal neoplasm, advanced (FIGO stage III-IV), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer (who responded to front-line platinum-based chemotherapy), Fallopian tube cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is pharmaand?

pharmaand (E5F8398) is a pharma company. headquartered in Wien, AT. listed on EMA. NovaPharmaNews links 1 pipeline program, 0 drugs, and 0 patents to this profile..

What pipeline programs does pharmaand sponsor?

We track 1 ClinicalTrials.gov-linked program for pharmaand, including Placebo for Opdivo, Rubraca 200 mg film-coated tablets, Rubraca 250 mg film-coated tablets, Rubraca 300 mg film-coated tablets, OPDIVO 10 mg/mL concentrate for solution for infusion., Placebo for Rubraca. Open each program for phase, modality, NCT IDs, and indication details.

Where does pharmaand company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.